WO2023170025 - AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS
National phase entry:
Publication Number
WO/2023/170025
Publication Date
14.09.2023
International Application No.
PCT/EP2023/055672
International Filing Date
07.03.2023
Title **
[English]
AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS
[French]
DÉRIVÉS D'AMIDO CYCLOPROPYLE EN TANT QU'INHIBITEURS DU RÉCEPTEUR DE LPA
Applicants **
CHIESI FARMACEUTICI S.P.A.
Via Palermo 26/A
43122 Parma, IT
Inventors
ARMANI, Elisabetta
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
AMARI, Gabriele
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
PAGANO, Mafalda
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
GIULIANI, Marta
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
Priority Data
22160914.2
08.03.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1710 | |
| EPO | Filing, Examination | 6487 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 6160 |
Total: 15526 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are amido cyclopropyl derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.[French]
La présente invention concerne des composés de formule générale (I) inhibant le récepteur 1 de l'acide lysophosphatidique (LPA1), en particulier l'invention concerne des composés qui sont des dérivés d'amido cyclopropyle, des procédés de préparation de tels composés, des compositions pharmaceutiques les contenant et leur utilisation thérapeutique. Les composés de l'invention peuvent être utiles dans le traitement de maladies ou d'états associés à un dérèglement des récepteurs de LPA, en particulier la fibrose.